Press Room

Article / Mar 17, 2017

Hovione establishes presence in Osaka

JETRO, March 17, 2017

Hovione, an established Portuguese pharmaceutical company, has opened a representative office in Osaka in June 2016 and now established Hovione K.K. in February 2017.

The company has been engaged in R&D and manufacturing of drug ingredients and compounds for more than 50 years since its foundation in 1959. Its strength lies in its expertise and advanced technology in areas such as inhalation development. It has expanded manufacturing sites in the US, Macau and Ireland. In Japan, Hovione distributes their Active Pharmaceutical Ingredients (API) for generic drugs to major pharmaceutical companies via sales agents, and it is also engaged in contracted development and manufacturing development as well as the particle engineering.

Hovione plans to apply for a license of Marketing Authorization Holder (MAH) and to obtain additional sales approval of its API.

For the establishment of Hovione’s base in Japan, the JETRO Invest Japan Business Support Center (IBSC) provided support such as consultation (corporate registration, labor affairs and tax matters) and invitation to Japan to assist the establishment of the base.

JETRO

 

ポルトガルの製薬会社Hovioneが大阪に進出

ポルトガルに本社を置く、老舗製薬会社であるHovione が2016年6月、大阪に日本駐在員事務所を開設し、 2017年2月にホビオン株式会社を設立した。

同社は、1959年の創業以来50年以上にわたり、原薬や化合物の研究開発と製造を行っており、特に吸入剤などの分野で高い技術を持っている。海外では、米国、マカオ、アイルランドにも製造工場を保有。日本では、代理店経由で大手製薬会社を対象に主にジェネリック医薬品(後発薬)向け原薬販売を行っているほか、受託開発製造、粒度設計などにも従事している。

今後は日本法人の医薬品製造販売認可や日本で販売する原薬の追加承認申請等を進めていく。

日本拠点設立に際し、ジェトロ対日投資・ビジネスサポートセンター(IBSC)は、拠点設立にかかるコンサルテーション(登記・労務・税務)、個別招へい等支援を行った。

JETRO / ジェトロ

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024